Home < About us < Overview
 
World class investigators for new drug development
Professional management with vast experience in medicine and biotech
Large scale government grants (US $30 Mil.)
Paid-in capital (US $10 Mil.)
Establishment of AmKor Pharma (US Branch)
M&A with EOLITH
 
Collaborations among industry, academia, and institutes for new drug development
Value added from the out-licensing of new late-stage drugs
Strategic alliances for R&D, in-licensing, and marketing
IT-based new drug development
 
Neu2000 (Stroke)
AAD-2004 (Alzheimer’s disease)
ND-07 (Inflammatory disease)
NP-07 (Pain)
 
 
Untitled Document